We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Ancon is designed to detect trace elements of things such as explosives, drugs and chemical weapons in the air. Ancon manufactures equipment and components that are up to 10,000 times more sensitive then anything else on the market.
days to go: Expired investment: £1,043,525
Ancon manufacture equipment and components that detect trace elements of explosives, drugs and chemical weapons in the air. Ancons technology is roughly 10,000 times more sensitive than anything currently on the market.
days to go: Expired investment: £1,043,525
Ancon technologies manufacture equipment and components to detect trace elements in the air, things such as explosives, drugs and chemical weapons. The technology created by Ancon is around 10,000x more sensitive than anything on the market at the moment. 
days to go: Expired investment: £457,000
Antev Limited (Antev) is a clinical-stage biopharmaceutical firm which focuses on the evolution of a drug used for prostate cancer, Teverelix TFA. The company is working on growing its copyright protection and is currently developing phase IIb clinical plans for prostate cancer. Antev is a pre-revenue company that aims at increasing its shareholder value by progressing the development of teverelix TFA towards registration whose approval is anticipated from 2023 onwards. The proceeds will be used for production, IP development, working capital and to develop a phase IIb repeat dosing clinical trial in prostate cancer.
days to go: Expired investment: Withheld
Antikor is developing a new cancer treatment using antibody fragment drug conjugate which penetrates solid tumours to destroy cancer cells. Their new treatment only targets pre-determined cancer cells, so healthy cells are not affected.  Biopharma is predicted to become the core of the pharmaceutical industry after undergoing transformation in the laboratory, technology and operations  
days to go: Expired investment: £125,000
Arca have introduced new tools for property risk management and created a marketplace to trade portfolio risks to match buyers and sellers of financial products connected to the performance of real estate. They are opening up the concept of short term property market risk management for property portfolio managers.  
days to go: Expired investment: £575,000
Arcade is an innovative provider of technology (patent pendinG) that empowers telecom carriers to offer life-changing gigabit broadband over existing networks, with rapid deployment and ROI in under a year. Their solutions enable gigabit speeds everywhere, complementing fiber strategies and avoiding extensive cable replacements.
days to go: Expired investment: £350,000
Aveqia is a unique interactive gastronomic experience combining a luxury restaurant with state of the art kitchens to create an exceptional venue for corporate events or private groups. These experiences are run by Michelin star trained chefs.
days to go: Expired investment: £100,000
Aveqia London is a unique interactive gastronomic experience combining a luxury restaurant with state of the art kitchens to create an exceptional venue for corporate events or private groups. Aveqia gives clients or colleagues the opportunity to work together to prepare and consume cuisine.
days to go: Expired investment: £100,000
Bikecation was formed in 2011 and specialise in package and bespoke cycling holidays in the UK and Europe.  They aim to provide holidays that capture the freedom and fun of cycling with a holiday that give you a thirst of adventure and an appetite for great food.  
days to go: Expired investment: £70,000
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph